Abstract
Background and Summary: Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used in the therapy of acute and chronic graft-versus-host disease (aGvHD, cGvHD) and other diseases. Based on the substantial efficacy and the excellent safety profile in the absence of immunosuppression ECP has established itself as a major treatment form for steroid-refractory GvHD. Here we review the current literature on ECP as a treatment option for patients with aGvHD as well as cGvHD. Key Messages: ECP is a well-established second-line therapy for cGvHD. Its role in the treatment of aGvHD is less clear but also points towards an effective second-line therapy option. In the future ECP could play a role in the prevention of GvHD. More experimental and randomized controlled trials are needed to define the best patient selection criteria, settings, and therapy regimens for GvHD.
Author supplied keywords
Cite
CITATION STYLE
Drexler, B., Buser, A., Infanti, L., Stehle, G., Halter, J., & Holbro, A. (2020, June 1). Extracorporeal Photopheresis in Graft-versus-Host Disease. Transfusion Medicine and Hemotherapy. S. Karger AG. https://doi.org/10.1159/000508169
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.